[Downloaded free from http://www.mmj.eg.net on Thursday, January 14, 2021, IP: 156.204.184.20] 778 Original article Hematological and biochemical changes due to anti-hepatitis C virus therapy Ashraf G. Dalaa, Mohamed H. Badra, Mohamed A. Helwab, Baher E. Maadawi Radia aDepartment of Internal Medicine, Faculty Objective b of Medicine, Menoufia University, Menoufia The aim of the study was to assess the hematological and biochemical changes in patients Hepatology Center, Menoufia, Egypt who have received anti‑hepatitis C virus (HCV) therapy before treatment and follow‑up after Correspondence to Baher E. Maadawi Radi, 3 months of treatment as regards the advantages and disadvantages through a follow up of MBBCh, Shabas Elshouhada, Dessouq, the studied patients. Kafr Al Sheikh 32717, Egypt Tel: +20 100 975 9737; Background e‑mail:
[email protected] There is a dramatic improvement in HCV therapy following the introduction of oral medicines that directly inhibit the replication cycle of HCV, so the follow up of patients who are receiving Received 26 December 2018 Revised 09 February 2019 therapy before and 6 months after treatment is mandatory to choose the best drug for each Accepted 12 February 2019 patient with the least side effects. Published 30 September 2020 Patients and methods Menoufia Medical Journal 2020, 33:778–782 This study was done on 200 patients admitted to the Kafr El‑Sheikh Hepatology Center diagnosed as HCV-infected patients. Those patients were classified according to the Child classification as Child A score 6. Of them, 100 patients received sofosbuvir + ledipasvir and another 100 patients received sofosbuvir + daclatasvir, respectively.